Limitations, Controversies, and Debates in Cardiac PET

Introduction

Every diagnostic test has limitations, and cardiac PET is no exception. Understanding where the technology falls short helps patients and physicians interpret results appropriately and avoid overreliance on any single piece of information. The limitations of cardiac PET relate to technical factors, patient characteristics, and fundamental constraints of perfusion imaging.

Controversies in the field reflect genuine scientific uncertainty about optimal use of cardiac PET compared to alternatives. Reasonable experts disagree about when to choose functional imaging over anatomic imaging, what constitutes appropriate indications, and how to standardize quantitative measurements. These debates have practical implications for patients navigating cardiac imaging decisions.

This article examines what cardiac PET cannot do well, situations where accuracy is compromised, and ongoing debates within the cardiovascular imaging community. Patients benefit from realistic expectations about what PET provides and awareness that the technology is not infallible. Related articles address fundamentals, how PET compares to alternatives, and clinical decision-making.

What are the main limitations of cardiac PET that patients should understand?

Cardiac PET provides excellent functional assessment but has inherent blind spots. The technology cannot visualize coronary artery anatomy, cannot distinguish different stenosis severities that produce similar functional effects, and depends on tracer kinetics that introduce quantitative uncertainty at high flow rates. No imaging test provides complete information, and PET is no exception.

The reliance on pharmacologic stress limits applicability in some patients. Those who cannot tolerate adenosine-based agents due to severe asthma or advanced heart block may not be candidates for standard protocols. Alternative stress agents exist but have their own limitations. Exercise stress with PET is technically challenging and not widely available.

Quantitative flow measurements, while valuable, carry measurement uncertainty that affects interpretation of borderline values. A reported CFR of 1.9 might actually be 1.7 or 2.1 given typical measurement variability (Schindler et al., 2010). Patients with values near diagnostic thresholds face uncertainty about their true disease status.

In what situations can cardiac PET produce false positive results?

False positives occur when the test indicates abnormality in patients without significant coronary disease. Motion artifact during acquisition can create apparent perfusion defects that mimic ischemia. Soft tissue attenuation from breast tissue or elevated diaphragm can reduce tracer counts in adjacent myocardium. Reconstruction artifacts from improper patient positioning affect image quality and interpretation (Bacharach et al., 2003).

Microvascular dysfunction represents a challenging category. Patients with reduced CFR but open coronary arteries have real pathology, but whether to classify these as true positives depends on the clinical question. If PET was ordered to detect epicardial coronary disease, finding microvascular dysfunction instead could be considered a false positive for the intended indication.

Small vessel disease from diabetes, hypertension, or other conditions impairs flow reserve without epicardial obstruction. These patients have genuinely abnormal PET findings that may not correspond to findings on coronary angiography. Understanding that PET detects microvascular disease explains apparent discordance with anatomic imaging.

In what situations can cardiac PET produce false negative results?

False negatives occur when significant coronary disease exists but PET fails to detect it. Balanced ischemia from severe three-vessel disease can produce uniformly reduced perfusion that appears normal on relative imaging because no territory looks worse than others. Quantitative flow assessment helps but may not completely eliminate this limitation (Nayfeh et al., 2023).

Single-vessel disease may produce subtle defects that fall below detection threshold, particularly in smaller territories or when stenosis severity is moderate. Left circumflex territory defects can be subtle due to the variable anatomy and smaller myocardial mass typically supplied by this vessel.

Caffeine consumption within 12-24 hours of testing can attenuate vasodilator response and reduce the ability to detect flow differences between normal and stenotic territories. Patients who do not follow preparation instructions may have false-negative studies despite significant coronary disease.

How does balanced ischemia challenge the accuracy of cardiac PET interpretation?

Balanced ischemia occurs when all three major coronary arteries have similar degrees of obstruction, producing uniform flow reduction without regional differences. Standard perfusion imaging compares territories to each other, so global abnormality can paradoxically appear normal when no region stands out as worse than others.

This phenomenon explains why severe three-vessel disease can sometimes be missed or underestimated by perfusion imaging. The ventricle appears to have uniform tracer uptake because flow is equally compromised everywhere. Visual interpretation alone may miss this pattern entirely (Chen et al., 2019).

Quantitative flow measurement directly addresses this limitation by measuring absolute flow rates rather than comparing territories. Globally reduced stress MBF and CFR indicate severe disease even when visual images appear unremarkable. This represents one of the strongest arguments for quantitative PET over purely qualitative imaging approaches.

Why might cardiac PET underestimate disease severity in patients with three-vessel coronary artery disease?

Beyond balanced ischemia, PET may underestimate three-vessel disease because the most abnormal territory serves as the reference for relative comparisons. If all territories are severely abnormal, the computer algorithm may normalize to the least abnormal territory, making all regions appear closer to normal than they truly are.

Collateral blood supply can also mask disease severity. When chronic severe stenosis develops, the heart often grows new small vessels that provide alternate routes for blood to reach downstream muscle. These collaterals may maintain adequate resting flow and partially preserve stress flow, reducing the apparent perfusion abnormality despite severe anatomic disease (Valenta and Schindler, 2024).

The practical implication is that PET finding of moderate ischemia in one territory may indicate more extensive disease if subtle abnormalities in other territories are present. Interpreting physicians look for secondary markers of severe disease including transient ischemic dilation, stress-induced wall motion abnormality, and reduced CFR.

What patient populations have reduced diagnostic accuracy with cardiac PET?

Patients with very large body habitus challenge PET imaging because increased soft tissue attenuation reduces detected counts and degrades image quality. The short half-life of rubidium-82 exacerbates this problem because there is limited time to acquire adequate counts. Some obese patients may require ammonia for acceptable image quality (Guduguntla and Weinberg, 2025).

Women with small hearts may have reduced accuracy due to partial volume effects. When myocardial walls are thin, tracer activity from adjacent blood pool or ventricle can contaminate myocardial measurements. This is more common in women due to typically smaller cardiac dimensions.

Patients with prior bypass surgery present interpretive challenges. Graft territories may not correspond to native coronary distributions, and scarring from surgery can create artifacts. Native vessel disease in the presence of grafts further complicates assessment. Prior revascularization history should inform interpretation.

How does atrial fibrillation or other arrhythmias affect cardiac PET accuracy?

Atrial fibrillation introduces irregular R-R intervals that complicate ECG gating. When gated imaging is required to assess wall motion or ejection fraction, irregular rhythms degrade data quality. Ungated imaging for perfusion assessment is less affected but may still show increased variability.

Frequent premature ventricular contractions during stress can affect hemodynamic response and tracer delivery. The timing of tracer injection relative to ectopic beats can influence how tracer distributes. Arrhythmia during imaging acquisition increases noise and may introduce artifacts (Munoz et al., 2018).

Complete heart block and other conduction abnormalities may preclude adenosine-based stress agents, limiting protocol options. Alternative approaches using dobutamine or exercise may be feasible but have different sensitivity characteristics. The interpreting physician should know the patient’s rhythm during imaging.

How does obesity affect cardiac PET image quality and interpretation?

Obesity affects cardiac PET through multiple mechanisms. Increased tissue attenuation between the heart and detectors reduces the number of photons that reach the scanner, lowering count statistics and increasing image noise. Scatter from photon interactions in soft tissue adds further noise.

The attenuation correction process using CT can be challenged by very large patients. Misalignment between PET and CT from respiratory motion or patient movement during the scan creates artifacts that appear as perfusion abnormalities. Careful attention to registration quality helps minimize these errors (Bacharach et al., 2003).

Practically, some obese patients may have studies that are technically limited despite optimization efforts. Facilities should be transparent with patients when image quality constraints affect diagnostic confidence. Repeat imaging with alternative tracers or protocols may be necessary in some cases.

What is the controversy around using cardiac PET versus anatomic imaging like CT angiography?

The debate centers on whether it is better to detect coronary plaque (anatomic approach) or ischemia (functional approach) as the initial evaluation strategy. CT angiography reveals the presence, extent, and composition of atherosclerotic plaque but does not determine if stenoses limit blood flow. Functional testing with PET identifies flow-limiting disease but misses non-obstructive plaque.

Proponents of anatomic imaging argue that plaque detection identifies patients at risk before stenoses become severe enough to cause symptoms or events. Finding even moderate plaque changes medical therapy and enables earlier preventive intervention (Pelletier-Galarneau et al., 2024). Missing this plaque with functional testing is considered a limitation.

Proponents of functional imaging counter that many patients have anatomic stenosis without functional significance. Treating non-flow-limiting lesions with revascularization does not improve outcomes. PET identifies which stenoses matter functionally and avoids unnecessary invasive procedures based on anatomy alone.

Why do some cardiologists prefer anatomic imaging while others prefer functional testing like PET?

Training background influences preferences. Interventional cardiologists comfortable with catheterization often favor anatomic imaging that directly informs procedural planning. Nuclear cardiologists trained in functional assessment may favor PET or SPECT. These practice patterns reflect professional perspective rather than evidence-based superiority of one approach.

Patient population also affects preferences. Anatomic imaging proponents argue it is optimal for symptomatic patients with intermediate pretest probability. Functional imaging proponents counter that it better identifies who needs intervention. Trial evidence supports both approaches in appropriate settings (Nayfeh et al., 2023).

Cost considerations enter the discussion differently depending on perspective. CT angiography is typically less expensive than PET for the initial test. However, anatomic findings often prompt additional functional testing, potentially increasing total evaluation cost. Analysis of downstream utilization data shows variable patterns across different initial testing strategies.

What is the debate about whether perfusion imaging or coronary calcium scoring better predicts outcomes?

Coronary calcium scoring quantifies calcified plaque burden and provides powerful long-term prognostic information. Zero calcium indicates very low short-term risk in most patients. High calcium scores predict elevated event rates over years to decades. The test is inexpensive and involves minimal radiation.

Perfusion imaging identifies current ischemia but has less prognostic power for patients without inducible perfusion defects. A normal perfusion study does not exclude significant plaque burden that might cause future events. Abnormal perfusion strongly predicts near-term risk but normal studies provide limited long-term reassurance (Schindler et al., 2010).

The two tests answer different questions. Calcium scoring identifies patients with atherosclerosis who need aggressive risk factor management. Perfusion imaging identifies patients with flow-limiting disease who need consideration of revascularization. Many patients benefit from both assessments, and some experts advocate combined protocols.

Is there inter-reader variability in cardiac PET interpretation and how significant is it?

Studies comparing independent readers show agreement rates of 80-90% for major diagnostic categories. Disagreement is more common for borderline cases, subtle abnormalities, and quantification of extent and severity. Reader experience correlates with agreement rates, with high-volume readers showing better consistency.

Quantitative measurements reduce variability compared to purely visual interpretation because computer-derived numbers do not depend on subjective assessment. However, the decision to call a quantitative value abnormal still requires judgment, particularly near threshold values. Automated interpretation aids improve consistency but do not eliminate reader differences (Schelbert et al., 2003).

For patients with borderline results affecting treatment decisions, second opinions from experienced readers may be valuable. Centers with higher volumes typically have more consistent interpretation due to accumulated experience and ongoing quality review. Reader qualifications and experience should be considered when evaluating where to have cardiac PET performed.

How does the lack of standardization across PET centers affect result comparability?

Different centers use different scanners, tracers, acquisition protocols, reconstruction parameters, and analysis software. Each of these factors affects quantitative results. A CFR of 2.0 measured at one facility might correspond to 2.3 or 1.7 at another facility due to systematic differences in methods.

Professional societies have published standardization recommendations, but implementation varies. Some centers follow guidelines closely while others use locally developed protocols. Ongoing efforts to harmonize cardiac PET aim to improve inter-center comparability (Guduguntla and Weinberg, 2025).

The practical implication for patients is that serial scans should ideally be performed at the same facility using consistent methods. Comparing results across different centers requires caution. If you must change facilities, informing the interpreting physician about prior studies enables appropriate contextualization of results.

What are the limitations of coronary flow reserve as a single metric?

CFR integrates information about epicardial coronary arteries and microvasculature into a single number. This simplicity is both strength and limitation. When CFR is abnormal, the test cannot determine whether epicardial stenosis, microvascular dysfunction, or both contribute. Additional testing may be needed to clarify the mechanism.

CFR depends on resting flow, which can be elevated by conditions including anemia, thyroid disease, and acute illness. High resting flow reduces the ratio even when stress flow is normal. Stress MBF provides complementary information not captured by CFR alone (Valenta and Schindler, 2024).

Regional versus global CFR patterns help distinguish epicardial from microvascular disease but do not definitively localize pathology. Patients with reduced CFR may undergo coronary angiography only to find open arteries, indicating microvascular disease. While this information is valuable, it illustrates CFR’s limited specificity for epicardial disease.

Can medications or caffeine intake affect results and lead to misinterpretation?

Caffeine blocks adenosine receptors, directly antagonizing the mechanism by which standard vasodilator stress agents work. Patients who consume caffeine within 12-24 hours of testing may have blunted stress response, reducing the ability to detect perfusion differences. This can produce false-negative results in patients with significant coronary disease.

Beta-blockers and calcium channel blockers reduce heart rate response to stress and may attenuate peak stress flow. While these medications do not absolutely preclude testing, they can reduce diagnostic sensitivity. Different protocols handle rate-controlling medications in different ways (Bacharach et al., 2003).

Nitrates and other vasodilators can affect coronary hemodynamics in ways that influence test results. Patients should follow specific preparation instructions provided by the imaging facility. When test results seem inconsistent with clinical presentation, inquiry about preparation compliance may be warranted.

What are the arguments for and against using cardiac PET in patients with known coronary artery disease?

Proponents argue that PET provides valuable functional information in patients with known CAD. Demonstrating ischemia extent and severity helps guide decisions about revascularization versus medical therapy. Quantitative flow assessment identifies patients at highest risk who might benefit from aggressive intervention.

Critics counter that coronary anatomy is already known in these patients, making additional functional assessment redundant in many cases. If significant stenoses exist and symptoms warrant treatment, anatomic information may suffice for procedural planning. The added cost of PET may not be justified when revascularization is clearly indicated or clearly inappropriate.

Appropriate use criteria support PET in selected patients with known CAD, particularly those with unclear symptom etiology, intermediate stenoses of uncertain significance, or need for viability assessment before revascularization (Chen et al., 2019). The decision should be individualized based on clinical circumstances.

Why do some experts argue that PET is overused while others argue it is underutilized?

Those arguing overuse point to PET ordering in low-risk patients unlikely to benefit, repeat testing without clear indication, and substitution of expensive PET for adequate but less costly alternatives. Payment incentives that favor PET over SPECT may drive utilization beyond what clinical appropriateness would support.

Those arguing underutilization note that most cardiac perfusion imaging in the US uses SPECT despite PET’s superior accuracy. Patients receive inferior diagnostic information when SPECT is used where PET would provide better assessment. Cost and availability barriers prevent appropriate PET access for many patients who would benefit (Pelletier-Galarneau et al., 2024).

Both perspectives contain validity. PET is likely overused in some clinical contexts while simultaneously underused in others. Appropriate use criteria attempt to define situations where PET adds value, but implementation varies. Individual patients should discuss with their physicians whether PET specifically is needed versus alternative approaches.

Conclusion

Cardiac PET has limitations that patients and physicians should understand when interpreting results and making treatment decisions. Technical constraints, patient factors, and fundamental aspects of perfusion imaging all contribute to situations where accuracy is reduced. No test is perfect, and realistic expectations improve clinical utility.

Ongoing controversies in the field reflect genuine scientific uncertainty about optimal imaging strategies. The debate between anatomic and functional imaging continues, and reasonable experts disagree about appropriate indications for cardiac PET. These debates should inform rather than paralyze clinical decision-making.

Understanding PET’s limitations helps patients ask informed questions about their results. Related articles address how PET compares to alternatives, guideline recommendations, and clinical decision-making. Awareness of uncertainty enables more nuanced discussions with physicians about what cardiac PET findings mean for individual care.